Snippet Below:

Scripintelligence - Indian expert group to re-examine spurious drug definitions Scrip Clinica RAJ Scrip Clinical Research AnimalPharm Email ID Password Forgotten your password? Sign me in automatically next time Advanced Search Home Therapy Sector Generics Business Policy & Regulation Research & Development International Pricing & Reimbursement | Regulation | Healthcare Policy | Pharmacovigilance | Intellectual Property | Scrip Indian expert group to re-examine spurious drug definitions 03 March 2010 Anju Ghangurde India has constituted an expert group to examine the definitions of spurious, adulterated and misbranded drugs in the Drugs and Cosmetic Act and recommend changes to these in the context of "present trade practices followed nationally and internationally". India's Drugs Technical Advisory Board... Please Login to read the full article. Not a subscriber? Request a FREE Trial Subscribe to Scrip RELATED CONTENT NEWS Scrip News Indian court rejects Bayer appeal against generic Nexavar Indian court rejects patent linkage in Bayer's sorafenib case - update Cipla's sorafenib priced at one-tenth of Nexavar in India Indian court rejects patent linkage in Bayer'ssorafenib case Other Informa News Big EU regulatory change ahead? 25 years’ overview spells caution US court urged to reject FDA bid to regulate e-cigarettes as devices ANALYSIS Scrip Analysis Executive Briefing – Health technology assessment: a brief look at the EU Executive Briefing - Getting to grips with advanced therapies in the EU Other Informa Analysis Gene genie: the role of devices in gene therapy delivery Cook's Biodesign website speaks the language of imagery COMMENT Scrip Comment Product liability, the aims of the Treaty and the ECJ Other Informa Comment New health tax a boon for German devices sector FEATURES Scrip Features GE Healthcare aims to end unpredictability in early drug research Interview: Croatia's state insurer changes its role to raise efficiency Other Informa Features BSI's Sue Spencer: new EC diagnostics proposals reflect GHTF thinking Review of 2009: EU regulations - when the going gets tough, the tough get going About Us Getting Started Subscribe Free Trial Advertise Awards White Papers JOB OF THE WEEK Promote your vacancy here © 2010 Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36 Home Therapy Sector Generics Business Policy & Regulation Research & Development International Terms & Conditions Privacy Policy Sitemap About Us Advertise Subscribe Scrip Clinica RAJ Scrip Clinical Research Animal Pharm